Emotra hereby announces that the company has signed a letter of intent with a large, London-based psychiatric hospital. This deal grants the hospital the right to use EDOR® during a limited trial period. The agreement includes 30 tests free of charge, after which...
Emotra has recently held a number of meetings with decision-makers who intend to move forward with testing of EDOR® in their regular clinical practice. The psychiatric caregivers that Emotra has met this autumn have grown increasingly aware of how EDOR test results...
Today, November 1, 2018, EMOTRA AB (“Emotra”) announced that its Board of Directors have decided on a new rights issue of shares. This rights issue will comprise a maximum of 23,978,953 shares and the public has also been invited to participate. 181101 -...
Emotra’s CEO announces that he is stepping down. Emotra’s board of directors has appointed Marketing Manager Daniel Poté as the new CEO. Daniel will assume this new position immediately. Margit Ferm has stated that she wishes to step down as chairperson of the board,...
The Board of Directors and the CEO of Emotra AB (publ) hereby present the interim report for the first nine months of 2018. 181024 Interim report Jan-Sept 2018
Yesterday, on October 17, 2018, Emotra hosted a training seminar for doctors and test leaders at a number of clinics that belong to a German psychiatric and psychotherapeutic hospital. This training is the start of a controlled introduction of the test in their...
Emotra has reached an important stage in its development. A few days ago, a scientific article was published based on a compilation of the results of earlier blind studies. It shows that hyporeactivity is a clear and strong marker for suicide risk. Furthermore, the...
A study conducted by Emotra’s Chief of Research and the inventor of EDOR®, Lars-Håkan Thorell, and the biostatistician Karl Wahlin demonstrates how strongly the company’s test identifies patients at risk of committing suicide. 180904- Emotra - PM - New...
The Board and CEO of Emotra AB (publ) hereby present the interim report for the first six months of 2018. 180822 Interim report Jan-June 2018
As we have previously announced, Japan is one of Emotra’s high-priority markets. The company has applied for patents in the EU, USA, Canada and Japan. The Japanese patent office has now informed us that Emotra’s Japanese patent application number 2016-516080 has been...
